文献速递糖尿病肥胖与代谢综合征

富含甘油三酯残粒脂蛋白颗粒直径增大可提升2型糖尿病风险预测

Increased particle size of triacylglycerol-enriched remnant lipoproteins, but not their plasma concentration or lipid content, augments risk prediction of incident type 2 diabetes.
PubMed 文献 · Diabetologia · 2020-11-07

在巴西成人健康纵向队列4463名高危个体中,平均随访3.7年后366例新发糖尿病。基于18个变量的模型整体AUROC为0.846,TRL相关指标整体与糖尿病无关,但TRL颗粒直径仅在基线HbA1c<39 mmol/mol(5.7%)者中提升预测 discrimination,该亚组测试集AUROC由0.717升至0.794。

要点

  • TRL颗粒直径可提升基线HbA1c<5.7%者的糖尿病风险预测。
  • 基线HbA1c 5.7-6.4%者中TRL颗粒直径未提升预测。
  • TRL血浆浓度及脂质含量整体与糖尿病发生无关。

核心结论

  • TRL颗粒直径可改善糖尿病预测,但仅限于基线HbA1c<39 mmol/mol(5.7%)的个体。

研究设计与样本

  • 巴西成人健康纵向队列研究,纳入4463名高危个体,平均随访3.7(±0.63)年。
  • 以80%队列十折交叉验证训练logistic回归模型,剩余20%为测试集。

主要发现

  • 随访期间共366例新发糖尿病。
  • 18变量模型整体AUROC为0.846(95%CI:0.829,0.869)。
  • TRL相关标志物整体与糖尿病无关联。
  • 基线HbA1c<39 mmol/mol(5.7%)亚组测试集(n=659)中,加入TRL颗粒直径后AUROC由0.717(95%CI 0.603,0.818)升至0.794(95%CI 0.731,0.862),AUPRC由0.582升至0.701。
  • 基线HbA1c 39-46 mmol/mol(5.7-6.4%)亚组测试集(n=233)中TRL颗粒直径未提升预测。

临床怎么用

  • 对基线HbA1c<5.7%的高危人群,可考虑将TRL颗粒直径纳入风险评估以优化糖尿病预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 2 diabetes prevention requires the accurate identification of those at high risk. Beyond the association of fasting serum triacylglycerols with diabetes, triacylglycerol-enriched remnant lipoproteins (TRLs) more accurately reflect pathophysiological changes that underlie progression to diabetes, such as hepatic insulin resistance, pancreatic steatosis and systemic inflammation. We hypothesised that TRL-related factors could improve risk prediction for incident diabetes. METHODS: We included individuals from the Brazilian Longitudinal Study of Adult Health cohort. We trained a logistic regression model for the risk of incident diabetes in 80% of the cohort using tenfold cross-validation, and tested the model in the remaining 20% of the cohort (test set). Variables included medical history and traits of the metabolic syndrome, followed by TRL-related measurements (plasma concentration, TRL particle diameter, cholesterol and triacylglycerol content). TRL features were measured using NMR spectroscopy. Discrimination was assessed using the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). RESULTS: Among 4463 at-risk individuals, there were 366 new cases of diabetes after a mean (±SD) of 3.7 (±0.63) years of follow-up. We derived an 18-variable model with a global AUROC of 0.846 (95% CI: 0.829, 0.869). Overall TRL-related markers were not associated with diabetes. However, TRL particle diameter increased the AUROC, particularly in individuals with HbA1c <39 mmol/mol (5.7%) (hold-out test set [n = 659]; training-validation set [n = 2638]), but not in individuals with baseline HbA1c 39-46 mmol/mol (5.7-6.4%) (hold-out test set [n = 233]; training-validation set [n = 933]). In the subgroup with baseline HbA1c <39 mmol/mol (5.7%), AUROC in the test set increased from 0.717 (95% CI 0.603, 0.818) to 0.794 (95% CI 0.731, 0.862), and AUPRC in the test set rose from 0.582 to 0.701 when using the baseline model and the baseline model plus TRL particle diameter, respectively. TRL particle diameter was highly correlated with obesity, insulin resistance and inflammation in those with impaired fasting glucose at baseline, but less so in those with HbA1c <39 mmol/mol (5.7%). CONCLUSIONS/INTERPRETATION: TRL particle diameter improves the prediction of diabetes, but only in individuals with HbA1c <39 mmol/mol (5.7%) at baseline. These data support TRL particle diameter as a risk factor that is changed early in the course of the pathophysiological processes that lead to the development of type 2 diabetes, even before glucose abnormalities are established. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Carvalho LSF, Benseñor IM, Nogueira ACC, et al. Increased particle size of triacylglycerol-enriched remnant lipoproteins, but not their plasma concentration or lipid content, augments risk prediction of incident type 2 diabetes. Diabetologia. 2020. PMID: 33159534. doi:10.1007/s00125-020-05322-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。